PMID- 16036028 OWN - NLM STAT- MEDLINE DCOM- 20051007 LR - 20191109 IS - 1546-9530 (Print) IS - 1546-9530 (Linking) VI - 1 IP - 2 DP - 2004 Jul TI - Initiation and use of beta-blockers in class IV heart failure. PG - 72-6 AB - Treatment of patients with heart failure caused by left ventricular systolic dysfunction using b-adrenergic receptor antagonists (or b-blockers) results in improvements in symptoms, hemodynamics, left ventricular remodeling, morbidity, and mortality. Most patients studied in prospective, randomized placebo-controlled trials have had New York Heart Association (NYHA) functional class II or III symptoms. The efficacy of b-blockers in treating NYHA class IV patients is not as well-established. This review summarizes the published experience regarding the use of b-blockers in patients with advanced heart failure. Although treatment requires considerable care, the data support attempts at initiation of b-blockers in this group of patients. FAU - Bader, Feras M AU - Bader FM AD - Division of Cardiology 4A100, University of Utah Health Sciences Center, 30 North 1900 East, Salt Lake City, UT 84132, USA. FAU - MacGregor, John F AU - MacGregor JF FAU - Gilbert, Edward M AU - Gilbert EM LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Heart Fail Rep JT - Current heart failure reports JID - 101196487 RN - 0 (Adrenergic beta-Antagonists) RN - 0 (Phosphodiesterase Inhibitors) SB - IM MH - Adrenergic beta-Antagonists/*therapeutic use MH - Female MH - Heart Failure/classification/*drug therapy/etiology MH - Hemodynamics/drug effects MH - Humans MH - Male MH - Middle Aged MH - Phosphodiesterase Inhibitors/therapeutic use MH - Prospective Studies MH - Randomized Controlled Trials as Topic MH - Ventricular Dysfunction, Left/complications RF - 26 EDAT- 2005/07/23 09:00 MHDA- 2005/10/08 09:00 CRDT- 2005/07/23 09:00 PHST- 2005/07/23 09:00 [pubmed] PHST- 2005/10/08 09:00 [medline] PHST- 2005/07/23 09:00 [entrez] AID - 10.1007/s11897-004-0029-0 [doi] PST - ppublish SO - Curr Heart Fail Rep. 2004 Jul;1(2):72-6. doi: 10.1007/s11897-004-0029-0.